logo-loader
viewCanntab Therapeutics Ltd

Full interview: Canntab receives indication of patentability for its release cannabidiol formulation

Canntab Therapeutics (CSE:PILL.CN-OTCQX: CTABF) Chief Financial Officer Richard Goldstein joined Steve Darling from Proactive Investors Vancouver on Skype with news that the company has received an initial assessment from the Geneva-based International Preliminary Report on Patentability regarding their Immediate Release Cannabidiol Formulation.


Goldstein talks about what that means for the company going forward and how this fall will be a defining moment for the company. 
 

Quick facts: Canntab Therapeutics Ltd

Price: 0.98 CAD

CSE:PILL
Market: CSE
Market Cap: $30.84 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Canntab Therapeutics Ltd named herein, including the promotion by the Company of Canntab Therapeutics Ltd in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Canntab Therapeutics raised 3 million dollars and receives...

Canntab Therapeutics (CSE: PILL-OTCQB: CTABF) CFO Richard Goldstein joined Steve Darling from Proactive in Vancouver to discuss the major announcement from the company that they have received their key Heath Canada Licence that allows them Processing & Sales for Medical...

on 3/3/20

2 min read